Protein Sciences calls on Connecticut to buy its flu vaccine

Protein Sciences is calling on its home state to kickstart its entry into the flu vaccine sector by purchasing its shot. The Connecticut-based biotech won approval for its flu vaccine last year but it faces competition from GlaxoSmithKline ($GSK), Sanofi ($SNY) and the other established giants of the market. Protein Sciences' vaccine differs from these rivals because it is made using an insect cell-based production process. Article

Suggested Articles

ebola
Vaccines

Merck’s Ebola vaccine appears to provide long-term shield: study

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

by Angus Liu
vaccine
Vaccines

Merck KGaA, Jenner hook up to improve vaccine manufacturing

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

by Angus Liu
gsk sign2
Vaccines

GSK’s Shingrix crowds out Merck in U.S. shingles vax market

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.

by Angus Liu